PRP where the dose actually lands.

PRP prepared to deliver a clinically meaningful platelet quantity, typically at or above the 10 billion platelet mark that recent peer reviewed literature associates with more consistent outcomes. Single spin and low volume systems often land at only 1 to 3 billion platelets per dose. High dose systems use validated dual spin protocols and optimised collection geometry to recover and concentrate platelets up to 30 times over baseline whole blood.

Sources: Bansal et al., Sci Rep 2021. Single spin range and 30× figure: Cervos data on file.

It's the threshold above which PRP studies start showing consistent improvement in pain and function scores. Doses below roughly 5.5 billion platelets have produced inconsistent results across the published literature, while doses meeting or exceeding 10 billion have shown sustained outcomes at one year follow up. KeyPRP is engineered to deliver platelet quantities in that range reliably.

Sources: Bansal et al., Sci Rep 2021 · Patel et al., OJSM 2024 · Everts et al., Biomedicines 2023.

Composition. Leukocyte poor PRP minimises white blood cells, particularly granulocytes, so leukocyte content usually sits below baseline whole blood levels. Leukocyte rich PRP keeps a higher concentration, generally several times above baseline. Which one you want is a clinical decision, made on the patient and the procedure. KeyPRP produces either from a single closed system.

Sources: DeLong et al., Arthroscopy 2012 · Mautner et al., PM&R 2015.

Double spin yields meaningfully higher platelet concentrations. Single spin is faster but typically delivers 2 to 5 times over baseline. The AABB aligned dual spin process in KeyPRP recovers more platelets and allows volume reduction down to 1.5 cc, reaching up to 30 times over baseline. The trade off is a slightly longer preparation step.

Sources: Magalon et al., Arthroscopy 2014. Concentration and minimum volume figures: KeyPRP data on file.

Across a wide range of orthobiologic and aesthetic applications. In orthopaedics and sports medicine the peer reviewed work covers knee osteoarthritis, tendinopathies and soft tissue applications. In aesthetics and dermatology it covers hair restoration and facial protocols. As always, clinical use is a decision for the treating clinician, based on the patient, the procedure and the evidence relevant to that application. We can send the full evidence pack on request.

Sources: Belk et al., AJSM 2021 · Filardo et al., KSSTA 2018 · Gupta & Carviel, Dermatol Surg 2016.

Yes. Rehacare runs KeyPRP demonstrations for clinicians in Australia and can arrange an evaluation kit. Use the enquiry form above and tell us your application and rough volumes.